π’ ππππ ππ: $Viking Therap(VKTX.US) Viking Therapeutics Reports Phase 2 Oral VK2735 Obesity Data
π πππ² ππ’π π‘π₯π’π π‘ππ¬:β€ Oral ππππππ achieved up to ππ.π% weight loss in ππ weeks.β€ Placebo group recorded π.π% average weight reduction.β€ Trial enrolled πππ adults with obesity or overweight conditions.β€ Weight loss began by π°πππ€ π and continued without plateauing.β€ Up to ππ% of participants achieved at least π% weight loss.β€ Treatment targets both πππ-π and πππ receptors.β€ Viking plans to launch ππ‘ππ¬π π trials for oral VK2735 this year.The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments